[Pregnancy after chemotherapy in malignant forms of gestational trophoblastic disease]. / Tehotenství po chemoterapii u maligních forem gestacní trofoblastické nemoci.

The authors reviewed the subsequent pregnancy experience in patients with malignant gestational trophoblastic disease who were managed at the Czechoslovak Trophoblastic Disease Center between January 1981 to December 1990. Thirty-five women who conceived following successful chemotherapy of gestational trophoblastic disease subsequently became pregnant a total of 53 times. Twenty-seven of these 53 pregnancies or 51% terminated in live-born infants. Major or minor congenital malformations were not detected. Those subsequent pregnancies concluded in 23 full-term deliveries (85%) and 4 premature births (15%). Primary cesarean section was performed for 5 (19%) women. Three or 6% ended in spontaneous abortion, one or 2% ended in mola hydatidosa partialis and mola hydatidosa completa. Sixteen pregnancies or 30% terminated in therapeutic abortion. Five women or 9% are now pregnant. Those patients who are treated successfully with chemotherapy should be reassured that they can anticipate a normal reproductive outcome in later conceptions.

[Hydatidiform changes in the chorion]. / Hydatiformní zmeny choria.

Revision of 630 cases of mola enabled a description of morphology in complete hydatid mole, partial hydatid mole, hydropic degeneration and their relation to the origin of trophoblastic disease. A survey covers pathogenesis of molar syndrome, cytogenetic findings and genetic methods for discrimination of complete and partial hydatid mole. To express grade of certainty in diagnostic of the lesions is recommended.

[Therapeutic and preventive care of trophoblastic disease in Czechoslovakia]. / Lécebne preventivní péce u trofoblastické nemoci v CSSR.

The authors list units of trophoblastic disease and its classification used and elaborated in the Centre for trophoblastic disease. The authors submit detailed information on the organization of diagnostic and therapeutic and preventive care of patients with trophoblastic disease in the CSSR. The authors draw attention to the establishment of a Centre for trophoblastic diseases (CTN) with the statute of a reference department. Reasons for its legalization are given. Its function and structure are described.

[Detection of hCG serum levels in choriocarcinoma using monoclonal antibodies]. / Sérové hladiny hCG u choriokarcinomu sledované pomocí monoklonálních protilátek.

hCG values and those of its alpha- and beta-subunits are assessed in the serum of all patients treated in the Centre of trophoblastic disease. Commercial RIA kits with conventional antibodies are used. There was an opportunity to work with kits of Serono Co. with monoclonal antibodies, the so-called hCG MAIA clone kit which assesses hCG and its beta-subunit. In this IRMA-MAIA system 240 sera of patients with choriocarcinoma were processed. Comparison of hCG values found in the IRMA-MAIA test with values assessed with kits from Kosice revealed the following: 33% of the values in MAIA were higher, 57% were in agreement. 10% of the specimens were MAIA negative, while the Kosice values were low (50-100 i.u./l) and a negative finding was assumed. The authors investigated low (or false positive) hCG values and values obtained during the so-called residual reaction. According to the obtained results in this system of three highly sensitive monoclonal antibodies no cross reaction with LH occurs.